Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide.
As a new drug R&D company led by an academician of the Chinese Academy of Engineering, Haihe Biopharma is committed to the path of independent innovation. It also has a research and management team with a global perspective, and it is proactively mapping out the international development of innovative drugs.
Currently, seven of the 9 core products in the Haihe's R&D pipeline have entered the clinical development stage, and four have obtained IND approval from the US FDA.
With support from top venture capitalists in life science and technology, Haihe is accelerating the clinical development and commercialization of innovative products, and strives to provide patients with safer and more effective drugs at the earliest possible time.
Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs, Haihe brings life-saving therapies to cancer patients worldwide.
Haihe completed worth
1.2 billion yuan Series B Funding
Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.
Haihe established its US office
Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan
Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise
Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer
Haihe completed Haihe completed $136.6 million Series A Funding
The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China
Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical
Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.